The Patent Finder

Medivation Prostate Therapeutics, Inc.

12 patents currently held · Updated Nov 19, 2026
3 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
2
Ending by 2030
Feb 2030
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due May 3, 2027
    The maintenance fee for Processes for the Synthesis of Diarylthiohydantoin and Diarylhydantoin Compounds (US 9,174,943) comes due May 3, 2027. Unpaid by Nov 3, 2027, it lapses early.
  • 1 fee due Jun 12, 2027
    The maintenance fee for Formulations of Enzalutamide (US 11,839,689) comes due Jun 12, 2027. Unpaid by Dec 13, 2027, it lapses early.
  • 1 fee due Oct 9, 2027
    The maintenance fee for Method for predicting response to breast cancer therapeutic agents and method of treatment of breast cancer (US 11,952,634) comes due Oct 9, 2027. Unpaid by Apr 10, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 8,524,755Specific diarylhydantoin and diarylthiohydantoin compounds
In force
 · USPTO record
In forceUSPTO record
US 9,023,879Specific Diarylhydantoin and Diarylthiohydantoin Compounds
In force
 · Medium confidence
In forceMedium confidence
US 9,174,943Processes for the Synthesis of Diarylthiohydantoin and Diarylhydantoin Compounds
In force
 · Medium confidence
In forceMedium confidence
US 9,517,229Treatment of Breast Cancer
In force
 · High confidence
In forceHigh confidence
US 10,111,861Treatment of Breast Cancer
In force
 · High confidence
In forceHigh confidence
US 11,839,689Formulations of Enzalutamide
In force
 · Low confidence
In forceLow confidence
US 12,447,128Formulations of Enzalutamide
In force
 · Low confidence
In forceLow confidence
US 12,502,357Formulations of Enzalutamide
In force
 · Medium confidence
In forceMedium confidence
US 10,196,693Method for Predicting Response to Breast Cancer Therapeutic Agents and Method of Treatment of Breast Cancer
In force
 · High confidence
In forceHigh confidence
US 11,186,876Method for predicting response to breast cancer therapeutic agents and method of treatment of breast cancer
In force
 · USPTO record
In forceUSPTO record
10 of 12 patents shown.
Pro members see all 12.
Pro members: see all 12 patents
Also on record, not counted in the 12: 3 patents in force now held by others. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

1 pending · 11 abandoned

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited